[go: up one dir, main page]

FR05C0027I1 - - Google Patents

Info

Publication number
FR05C0027I1
FR05C0027I1 FR05C0027C FR05C0027I1 FR 05C0027 I1 FR05C0027 I1 FR 05C0027I1 FR 05C0027 C FR05C0027 C FR 05C0027C FR 05C0027 I1 FR05C0027 I1 FR 05C0027I1
Authority
FR
France
Prior art keywords
conopeptide
omega
medicament
manufacture
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/496,847 external-priority patent/US5795864A/en
Priority claimed from US08/613,400 external-priority patent/US6054429A/en
Application filed filed Critical
Publication of FR05C0027I1 publication Critical patent/FR05C0027I1/fr
Application granted granted Critical
Publication of FR05C0027I2 publication Critical patent/FR05C0027I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Control Of El Displays (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
FR05C0027C 1995-06-27 2005-06-23 Active FR05C0027I2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/496,847 US5795864A (en) 1995-06-27 1995-06-27 Stable omega conopetide formulations
US08/613,400 US6054429A (en) 1996-03-08 1996-03-08 Epidural method of producing analgesia
PCT/US1996/011041 WO1997001351A1 (en) 1995-06-27 1996-06-26 Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders

Publications (2)

Publication Number Publication Date
FR05C0027I1 true FR05C0027I1 (es) 2005-08-12
FR05C0027I2 FR05C0027I2 (es) 2006-12-29

Family

ID=27052304

Family Applications (1)

Application Number Title Priority Date Filing Date
FR05C0027C Active FR05C0027I2 (es) 1995-06-27 2005-06-23

Country Status (14)

Country Link
EP (2) EP0835126B1 (es)
JP (1) JP2838073B2 (es)
AT (2) ATE235914T1 (es)
AU (1) AU695166B2 (es)
CA (1) CA2224795C (es)
DE (3) DE69637021T2 (es)
DK (2) DK1336409T3 (es)
ES (2) ES2194998T3 (es)
FR (1) FR05C0027I2 (es)
HK (1) HK1058146A1 (es)
LU (1) LU91181I2 (es)
NL (1) NL300201I2 (es)
PT (2) PT1336409E (es)
WO (1) WO1997001351A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
CA2319038A1 (en) * 1998-02-20 1999-08-26 Zeneca Limited Analgesic peptides from venom of grammostola spatulata and use thereof
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
WO2004050688A1 (en) 2002-12-02 2004-06-17 Xenome Ltd NOVEL χ-CONOTOXIN PEPTIDES (-II)
CA2508129C (en) 2002-12-02 2012-06-26 Xenome Ltd Novel x-conotoxin peptides (-i)
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ATE365174T1 (de) 2003-01-28 2007-07-15 Microbia Inc Zusammensetzungen zur behandlung von gastrointestinalen störungen
EP1689401A1 (en) 2003-10-02 2006-08-16 Elan Pharmaceuticals, Inc. Method for reducing pain
GB0410215D0 (en) * 2004-05-07 2004-06-09 Lescroart Pol Nerve damage
US8188048B2 (en) 2006-06-23 2012-05-29 Xenome Limited Combination therapy
CN101557820A (zh) * 2006-11-04 2009-10-14 安奈根株式会社 ω芋螺毒素
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20110129508A1 (en) * 2008-05-06 2011-06-02 Relevare Aust. Pty Ltd Methods and compositions for the management of pain using omega-conotoxins
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
ES2608050T3 (es) 2008-12-03 2017-04-05 Synergy Pharmaceuticals Inc. Formulaciones de agonistas de guanilato ciclasa C y métodos de uso
KR101683318B1 (ko) 2008-12-31 2016-12-07 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014029983A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
RU2675364C2 (ru) 2013-04-12 2018-12-19 Арделикс, Инк Nhe3-связывающие соединения и способы ингибирования транспорта фосфатов
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
CN118221656A (zh) 2017-01-09 2024-06-21 阿德利克斯股份有限公司 可用于治疗胃肠道病症的化合物
US11147884B2 (en) 2017-01-09 2021-10-19 Ardelyx, Inc. Inhibitors of NHE-mediated antiport

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3926287A1 (de) * 1989-08-09 1991-02-21 Bernhard Clasbrummel Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
WO1993010145A1 (en) * 1991-11-12 1993-05-27 Neurex Corporation Compositions for delayed treatment of ischemia-related neuronal damage
ATE165977T1 (de) * 1991-12-30 1998-05-15 Neurex Corp Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie
JPH06247879A (ja) * 1993-02-17 1994-09-06 Bristol Myers Squibb Co デオキシチミジンヌクレオシドを含有する注射用製剤の安定化方法およびその方法によって得られる安定化注射用製剤

Also Published As

Publication number Publication date
DE122005000043I1 (de) 2006-06-29
JPH09104634A (ja) 1997-04-22
WO1997001351A1 (en) 1997-01-16
DK0835126T3 (da) 2003-07-14
FR05C0027I2 (es) 2006-12-29
EP1336409A1 (en) 2003-08-20
DE69637021T2 (de) 2008-01-10
HK1058146A1 (en) 2004-05-07
NL300201I2 (nl) 2006-02-01
ATE235914T1 (de) 2003-04-15
DE122005000043I2 (de) 2006-08-03
DE69637021D1 (de) 2007-05-24
DK1336409T3 (da) 2007-08-13
EP0835126B1 (en) 2003-04-02
EP1336409B1 (en) 2007-04-11
PT1336409E (pt) 2007-06-29
NL300201I1 (nl) 2005-09-01
ES2194998T3 (es) 2003-12-01
AU695166B2 (en) 1998-08-06
CA2224795C (en) 2001-04-03
ATE359086T1 (de) 2007-05-15
PT835126E (pt) 2003-07-31
DE69627153T2 (de) 2003-12-04
ES2283671T3 (es) 2007-11-01
DE69627153D1 (de) 2003-05-08
JP2838073B2 (ja) 1998-12-16
AU6400296A (en) 1997-01-30
CA2224795A1 (en) 1997-01-16
LU91181I2 (fr) 2005-09-06
EP0835126A1 (en) 1998-04-15

Similar Documents

Publication Publication Date Title
FR05C0027I2 (es)
HK1008180A1 (en) Use of vitamin d 2 or vitamin d 4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism
AUPM864894A0 (en) Treatment of bowel-dependent neurological disorders
ZA969520B (en) Use of epinastine for the treatment of pain
IL121170A0 (en) Compositions for the treatment of dermatological disorders
ZA9610139B (en) Treatment of the cns effects of hiv
AU7545594A (en) Implantable device for the treatment of aedemas
GB9603556D0 (en) Well treatment
EP0806897A4 (en) OSMOTIC REGULATOR
GB9512290D0 (en) Uses of polyhexanide
AU6328696A (en) Treatment of hemoglobinopathies
AU3105095A (en) Device for ensuring that medication is taken at the correct time
AU1578295A (en) Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders
AU7310896A (en) Use of nitroflavonoids for the treatment of anxiety
GB9303157D0 (en) Treatment of a group of related disorders
EP0765661A3 (en) Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of glumerulonephritis
AP9200355A0 (en) "Therapeutic agent"
HU9502623D0 (en) Use of substituted alkyl-nitrates for the treatment of pathologically increased intraocular pressure
GB9419048D0 (en) Treatment of muscular disorders
AU7726796A (en) Use of 3-oxa-d-prostaglandins for the manufacture of a medicament for the treatment of glaucoma
ZA947912B (en) Treatment of medical disorders associated with free radical formation
SI0778025T1 (en) Use of 8,9-dehydroestrone for the manufacture of a medicament for the treatment of diseases caused by free radicals
AU5419894A (en) Dental treatment aid
GB9505681D0 (en) "Treatment"
AU5397994A (en) Treatment of skin disorders